| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/BIMJ.201300248 |
| P698 | PubMed publication ID | 25619173 |
| P50 | author | Shahrul Mt-Isa | Q37831419 |
| Richard M. Nixon | Q50130162 | ||
| Thaison Tong | Q86594247 | ||
| P2093 | author name string | Andrew Thomson | |
| Silvia Kuhls | |||
| John Pears | |||
| Gemma Hodgson | |||
| Ed Waddingham | |||
| Kimberley Hockley | |||
| Christoph Dierig | |||
| Isabelle Stöckert | |||
| P2860 | cites work | The Magical Number Seven, Plus or Minus Two | Q1542532 |
| Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring | Q28243804 | ||
| Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group | Q28293763 | ||
| A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis | Q29616119 | ||
| Graphical perception and graphical methods for analyzing scientific data | Q31125203 | ||
| Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) | Q34375520 | ||
| Spurious precision? Meta-analysis of observational studies | Q37150008 | ||
| A Bayesian approach to evaluating net clinical benefit allowed for parameter uncertainty | Q45223311 | ||
| Development of a framework for enhancing the transparency, reproducibility and communication of the benefit-risk balance of medicines. | Q51624577 | ||
| Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response | Q56828560 | ||
| Application of the BRAT Framework to Case Studies: Observations and Insights | Q57847675 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 8-27 | |
| P577 | publication date | 2015-01-26 | |
| P1433 | published in | Biometrical Journal | Q15720842 |
| P1476 | title | A case study using the PrOACT-URL and BRAT frameworks for structured benefit risk assessment | |
| P478 | volume | 58 |
| Q38583668 | A Note on the Validity and Reliability of Multi-Criteria Decision Analysis for the Benefit-Risk Assessment of Medicines |
| Q90344383 | A novel measure of drug benefit-risk assessment based on Scale Loss Score |
| Q52725841 | A simple way to unify multicriteria decision analysis (MCDA) and stochastic multicriteria acceptability analysis (SMAA) using a Dirichlet distribution in benefit-risk assessment. |
| Q33834239 | Advancing regulatory science, advancing regulatory practice. |
| Q98830300 | Benefit-Risk Assessment of Esketamine Nasal Spray versus Placebo in Treatment-Resistant Depression |
| Q93135887 | Benefit-risk evaluation: the past, present and future |
| Q36533079 | Implementation of AMNOG: An industry perspective |
| Q90043415 | Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art |
| Q38981425 | Pharmaceutical Benefit-Risk Communication Tools: A Review of the Literature. |
| Q89865207 | Systematic benefit-risk assessment for buprenorphine implant: a semiquantitative method to support risk management |
| Q38681340 | Use of multicriteria decision analysis for assessing the benefit and risk of over-the-counter analgesics. |
Search more.